Loading market dashboard
Lyell Immunopharma, Inc.
LYELHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
SOUTH SAN FRANCISCO, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that the Company will present data from its ongoing Phase 1/2 clinical trial of rondecabtagene autoleucel (ronde-cel) in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) at the European Hematology Association (EHA) 2026 Congress, taking place in Stockholm, Sweden, June 11–14, 2026. The data will be featured in two poster presentations covering an updated ronde-cel safety analysis and translational insights.
Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Monday, June 8, 2026, in Miami, Florida, with a fireside chat scheduled for 11:20 am Eastern Time.
Lyell Immunopharma NASDAQ: LYEL President and CEO Lynn Seely outlined the company's clinical development priorities, regulatory strategy and manufacturing plans during a Stifel investor session moderated by Stephen Willey, senior biotech analyst at Stifel.
Lyell Immunopharma, Inc. (LYEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript
Lyell Immunopharma, Inc. (LYEL) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference Transcript
Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the following investor conferences: H.C.
PiNACLE pivotal clinical trial evaluating ronde-cel in patients with LBCL in third- or later-line setting on track to report additional data in second half of 2026, with pivotal data expected mid-2027 and BLA submission expected to follow in 2027 PiNACLE-H2H, a first of its kind Phase 3 clinical trial evaluating ronde-cel head-to-head against standard-of-care CD19 CAR T-cell therapies in the LBCL second-line setting, commenced patient dosing Phase 1 clinical trial of LYL273 continues to enroll patients with metastatic colorectal cancer, with commencement of patient dosing at Dose Level 3 Closed second $50 million tranche of $100 million private placement at $25.61 per share, with approximately $261 million in cash as of March 31, 2026, expected to provide runway into Q3 2027 SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today reported financial results and business highlights for the first quarter ended March 31, 2026.
Lyell Immunopharma, Inc. (NASDAQ: LYEL - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totaling 1,138,296 shares, an increase of 21.1% from the March 15th total of 940,269 shares. Currently, 6.3% of the company's stock are short sold. Based on an
Lyell Immunopharma, Inc. (LYEL) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
SOUTH SAN FRANCISCO, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will present and participate in the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026, at 11:00 am Eastern Time.
Mangoceuticals (NASDAQ: MGRX - Get Free Report) and Lyell Immunopharma (NASDAQ: LYEL - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations. Profitability This table compares Mangoceuticals and Lyell Immunopharma's
Lyell Immunopharma is a CAR-T developer with a single pivotal asset, ronde-cel, targeting LBCL and showing superior early efficacy and safety data. Ronde-cel's 93% ORR, 76% CR, and ~18-month mPFS in 3L+ LBCL patients outperformed approved peers, supporting a $1B+ peak sales opportunity. Valuation estimates suggest LYEL equity value of ~$45–55 per share, with the current price reflecting moderate success probability; pivotal data in 2027 is key.
SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2025. Lyell has since commenced patient dosing in the first-of-its-kind Phase 3 head-to-head CAR T-cell randomized controlled clinical trial of rondecabtagene autoleucel (ronde-cel) versus investigator's choice of axicabtagene ciloleucel (axi-cel) or lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) with disease progression on at least one prior line of therapy (PiNACLE-H2H). Lyell has dosed seven new patients with metastatic colorectal cancer (mCRC) with LYL273, an enhanced guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate, since its November 2025 acquisition, without dose-limiting toxicity and including dose escalation to Dose Level 3.
Stock News U.S. pump prices jump on war-driven supply shock: Average U.S. gasoline rose to about $3.54/gal, the highest since midâ2024, as the U.S.âIran con
SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced it has closed the sale of an additional $50 million of shares of its common stock to investors from its July 2025 equity private placement of up to $100 million, following achievement of a clinical milestone within its PiNACLE pivotal trial evaluating rondecabtagene autoleucel (ronde-cel) in patients with relapsed/refractory large B-cell lymphoma (LBCL) in the third- or later-line setting. The Company also announced the appointment of Smital Shah as its Chief Financial and Business Officer, effective March 9, 2026.
